Health Headlines: From New Drug Sales to Genetic Breakthroughs
In recent health news, Bristol Myers and Pfizer plan to sell Eliquis at a discount, aiming to aid uninsured patients. Meanwhile, the UK's three-person IVF technique saves eight children from genetic diseases. The FDA approves Juul's e-cigarettes and Green Needle completes a profitable quarter amidst tariff challenges.
In a move aimed at addressing high drug prices, Bristol Myers and Pfizer announced plans to sell their blood thinner, Eliquis, directly to American patients at a discounted rate. While this initiative seeks to assist uninsured or underinsured patients, experts warn the pricing may still be unaffordable for many.
Scientists in the UK have made strides in genetic disease prevention, utilizing a groundbreaking three-person IVF technique to spare eight children from devastating conditions. This technique, prohibited in the U.S., involves transferring genetic material from parents into a donor egg.
Additionally, the U.S. FDA has approved Juul Labs' tobacco and menthol flavored e-cigarettes, allowing the company to re-enter the market amidst growing regulatory scrutiny and diminishing sales.
(With inputs from agencies.)
- READ MORE ON:
- health
- drug pricing
- IVF
- e-cigarettes
- FDA approval
- genetic diseases
- Eliquis
- Juul
- tariffs
- Shingrix
Google News